In Brief: Ohmeda I-NOvent:
This article was originally published in The Gray Sheet
Ohmeda I-NOvent: FDA's Anesthesiology and Respiratory Therapy Devices Panel recommends downclassification from Class III to Class II with special controls of Ohmeda's system for nitric oxide administration at a Nov. 22 meeting in Rockville, Maryland. Ohmeda submitted a downclassification petition to FDA in September. I-NOvent, which comprises a nitric oxide administration apparatus and two separate devices to monitor nitric oxide gas and nitric dioxide gas concentration, is intended for inhaled nitric oxide therapy to treat pulmonary hypertension and lung disease conditions. FDA expects to publish a draft guidance on nitric oxide therapy systems in early 1997...
You may also be interested in...
A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.
Aker BioMarine seeks supplement firms to use its EPA/DHA innovation bound by lysophosphatidylcholine to enable the fatty acids to pass through the blood-brain and blood-retinal barriers and boost of eye and brain health benefits. It will submit an NDI notificaion in the US during 2022.
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.